Skip to Content

Ridaura (auranofin) Disease Interactions

There are 2 disease interactions with Ridaura (auranofin):

Major

Auranofin (Includes Ridaura) ↔ bone marrow aplasia

Severe Potential Hazard, High plausibility. Applies to: Bone Marrow Depression/Low Blood Counts

The use of auranofin and other gold compounds is contraindicated in patients with a history of gold- induced bone marrow aplasia. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy. Hematological warning signs of gold toxicity include a drop in hemoglobin, leukopenia (WBC < 4,000/mm3), granulocytopenia (< 1,500/mm3), and thrombocytopenia (<100,000/mm3).

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
Major

Auranofin (Includes Ridaura) ↔ gold induced disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Inflammatory Bowel Disease, Dermatitis - Drug-Induced, Infectious Diarrhea/Enterocolitis/Gastroenteritis, Idiopathic Pulmonary Fibrosis

The use of auranofin is contraindicated in patients with a history of any of the following gold- induced disorders: anaphylactic reactions, necrotizing enterocolitis, pulmonary fibrosis, and exfoliative dermatitis.

References

  1. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.

Ridaura (auranofin) drug interactions

There are 120 drug interactions with Ridaura (auranofin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide